Ruxolitinib + Ruxolitinib Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis With High Molecular Risk Mutations
Conditions
Myelofibrosis With High Molecular Risk Mutations
Trial Timeline
Feb 3, 2016 → Oct 23, 2017
NCT ID
NCT02598297About Ruxolitinib + Ruxolitinib Placebo
Ruxolitinib + Ruxolitinib Placebo is a phase 3 stage product being developed by Novartis for Myelofibrosis With High Molecular Risk Mutations. The current trial status is terminated. This product is registered under clinical trial identifier NCT02598297. Target conditions include Myelofibrosis With High Molecular Risk Mutations.
What happened to similar drugs?
2 of 18 similar drugs in Myelofibrosis With High Molecular Risk Mutations were approved
Approved (2) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02598297 | Phase 3 | Terminated |
Competing Products
20 competing products in Myelofibrosis With High Molecular Risk Mutations
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 36 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 39 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 35 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 40 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 21 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 26 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 44 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 27 |
| AZD1480 | AstraZeneca | Phase 1 | 29 |
| Bomedemstat | Merck | Phase 2 | 31 |
| Peginterferon alfa-2a | Merck | Phase 2 | 27 |
| Bomedemstat | Merck | Phase 1/2 | 32 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 21 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 29 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 32 |
| Imatinib mesylate | Novartis | Phase 2 | 35 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 24 |
| Ruxolitinib | Novartis | Pre-clinical | 30 |
| ruxolitinib | Novartis | Phase 2 | 35 |